Growth momentum for its US specialty drug portfolio, acquisitions, and outperformance in the domestic pharma market may sustain the returns trajectory of the country’s largest drugmaker, Sun Pharmaceutical Industries (Sun Pharma). The stock is the second-biggest gainer among the Nifty Pharma constituents with returns of 56 per cent over the past year.
Even as its peers are facing high single-digit price erosion, the impact on Sun Pharma is less, given its focus on a specialty drug portfolio. Quarter-to-date sales and volumes remain strong for most of its key specialty products in the US market. Rahul Jeewani and Punit Pujara of IIFL